Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMar 31, 2025
DataAggregated Company Financials
Companies568
- 7D-2.3%
- 3M-0.8%
- 1Y-8.9%
- YTD-1.9%
Over the last 7 days, the Biotech industry has dropped 2.3%, driven by a pullback from AbbVie of 1.9%. Overall the industry is down 8.9% in 12 months. As for the next few years, earnings are expected to grow by 28% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 01 Apr 2025 | US$816.7b | US$118.6b | -US$36,941,707,628.60 | 24.4x | -22.1x | 6.9x |
| Thu, 27 Feb 2025 | US$846.4b | US$117.5b | -US$37,773,216,777.42 | 17.1x | -22.4x | 7.2x |
| Sat, 25 Jan 2025 | US$989.8b | US$149.5b | -US$26,320,970,275.68 | 17.2x | -37.6x | 6.6x |
| Mon, 23 Dec 2024 | US$956.2b | US$149.9b | -US$26,389,992,070.38 | 15.7x | -36.2x | 6.4x |
| Wed, 20 Nov 2024 | US$990.2b | US$150.0b | -US$26,773,675,559.72 | 17.2x | -37x | 6.6x |
| Fri, 18 Oct 2024 | US$914.8b | US$113.1b | -US$35,984,216,716.86 | 21.7x | -25.4x | 8.1x |
| Sun, 15 Sep 2024 | US$932.2b | US$113.2b | -US$36,059,145,110.59 | 23.4x | -25.9x | 8.2x |
| Tue, 13 Aug 2024 | US$862.5b | US$112.7b | -US$36,817,276,448.41 | 21.6x | -23.4x | 7.7x |
| Thu, 11 Jul 2024 | US$1.2t | US$164.5b | -US$28,073,053,814.91 | 28.5x | -41.1x | 7x |
| Sat, 08 Jun 2024 | US$1.2t | US$164.5b | -US$26,778,554,526.26 | 28.1x | -43.3x | 7x |
| Mon, 06 May 2024 | US$1.1t | US$163.7b | -US$26,731,775,868.34 | 24.3x | -42x | 6.9x |
| Wed, 03 Apr 2024 | US$1.2t | US$164.3b | -US$23,551,987,061.81 | 23.5x | -49.8x | 7.1x |
| Fri, 01 Mar 2024 | US$1.2t | US$167.8b | -US$21,392,405,891.30 | 15.9x | -56x | 7.1x |
| Sun, 28 Jan 2024 | US$1.4t | US$204.7b | -US$22,652,938,045.00 | 18.3x | -63.1x | 7x |
| Tue, 26 Dec 2023 | US$1.4t | US$204.9b | -US$22,199,973,627.00 | 19.4x | -61.8x | 6.7x |
| Thu, 23 Nov 2023 | US$1.2t | US$204.7b | -US$22,048,392,183.00 | 17.9x | -55.5x | 6x |
| Sat, 21 Oct 2023 | US$1.2t | US$207.4b | -US$13,088,260,702.00 | 16.6x | -93.6x | 5.9x |
| Mon, 18 Sep 2023 | US$1.3t | US$207.5b | -US$12,865,929,372.00 | 17.5x | -99.8x | 6.2x |
| Wed, 16 Aug 2023 | US$1.3t | US$207.7b | -US$12,305,774,462.00 | 18x | -104.4x | 6.2x |
| Fri, 14 Jul 2023 | US$1.1t | US$186.7b | -US$15,961,677,744.00 | 13.2x | -70.8x | 6.1x |
| Sun, 11 Jun 2023 | US$1.1t | US$186.0b | -US$15,970,598,297.00 | 11.7x | -71.6x | 6.1x |
| Tue, 09 May 2023 | US$1.2t | US$192.6b | -US$12,055,565,323.00 | 15.7x | -96.6x | 6x |
| Thu, 06 Apr 2023 | US$1.2t | US$216.9b | -US$5,780,676,383.00 | 14.8x | -199.9x | 5.3x |
| Sat, 04 Mar 2023 | US$1.2t | US$199.0b | -US$4,941,026,359.00 | 16.5x | -233.1x | 5.8x |
| Mon, 30 Jan 2023 | US$1.2t | US$203.8b | US$1.8b | 14.8x | 662.7x | 5.7x |
| Wed, 28 Dec 2022 | US$1.1t | US$203.3b | US$1.7b | 14.1x | 680.9x | 5.6x |
| Fri, 25 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.6x | 844.9x | 5.6x |
| Sun, 23 Oct 2022 | US$1.1t | US$206.2b | US$5.3b | 15.8x | 200.9x | 5.2x |
| Tue, 20 Sep 2022 | US$1.1t | US$206.6b | US$5.9b | 14.7x | 180.2x | 5.1x |
| Thu, 18 Aug 2022 | US$1.1t | US$206.6b | US$7.3b | 16.2x | 151x | 5.3x |
| Sat, 16 Jul 2022 | US$1.1t | US$211.3b | US$10.7b | 17.2x | 101.3x | 5.1x |
| Mon, 13 Jun 2022 | US$957.4b | US$212.3b | US$11.0b | 15.6x | 86.9x | 4.5x |
| Wed, 11 May 2022 | US$969.2b | US$210.3b | US$12.1b | 13.9x | 79.8x | 4.6x |
| Fri, 08 Apr 2022 | US$1.3t | US$226.8b | US$14.3b | 18.8x | 91.7x | 5.8x |
Price to Earnings Ratio
91.7x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.3x is lower than the industry's current PS ratio of 6.9x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 19% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -3.46% | |
| Healthcare | -2.31% | |
| Biotech | -2.32% | |
| Biotech | -2.32% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GILD Gilead Sciences | US$111.79 | 4.7% +US$6.3b | 53.4% | PE290x | |
| ONC BeiGene | US$267.39 | 5.6% +US$1.5b | 67.9% | PS7.5x | |
| SLNO Soleno Therapeutics | US$71.99 | 46.6% +US$1.0b | 68.2% | PB13.5x | |
| IBRX ImmunityBio | US$3.14 | 10.2% +US$247.5m | -41.0% | PS181.7x | |
| ZLAB Zai Lab | US$37.29 | 4.5% +US$176.8m | 123.0% | PS10.2x |